The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
 
Arne Rainer Trummer
Honoraria - AstraZeneca; Bayer/Vital; Boehringer Ingelheim; Bristol Myers Squibb; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer/Vital; Boehringer Ingelheim; Bristol Myers Squibb; MSD Oncology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; MSD Oncology
 
Andre Bethge
No Relationships to Disclose
 
Nicolas J. Dickgreber
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Pfizer; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Pfizer; MSD Oncology; Roche; Takeda
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche; Takeda
 
Ina Dittrich
Consulting or Advisory Role - AstraZeneca; Boehringer Pharma GmbH; Bristol-Myers Squibb; Pfizer; Roche
 
Heiko Golpon
No Relationships to Disclose
 
Petra Hoffknecht
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Johnson & Johnson/Janssen; Lilly Foundation; MSD Oncology; Pfizer; Roche Pharma AG; Takeda
 
Tobias R. Overbeck
Consulting or Advisory Role - AstraZeneca; BMS; Boehringer Ingelheim; Lilly; MSD; Novartis; Pfizer/EMD Serono; Roche; Takeda; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Claas Wesseler
Honoraria - AstraZeneca/MedImmune; BMS; Boehringer Ingelheim; Novartis; Roche/Genentech; Takeda
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis